Skip to content

OUR COMPANY

We are a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ophthalmic diseases

OUR MISSION

Kodiak aims to prevent and treat the leading causes of blindness in the developed world

TRAILBLAZING SCIENCE

OUR CREATIVE AND THOUGHTFUL FOUNDATION

“GO-TO” MEDICINES

OUR CHALLENGE TO THE STATUS QUO

SINGULAR FOCUS IN OPHTHALMOLOGY

OUR 24/7/365

THE TEAM

Together, our team has acquired decades of experience needed to solve some of the most challenging issues in ophthalmology

Victor Perlroth, M.D.
Chairman and Chief Executive Officer
John Borgeson
Chief Financial Officer
Jason Ehrlich, M.D., Ph.D.
Chief Medical Officer and Chief Development Officer

Hong Liang, Ph.D.
Senior Vice President, Discovery Medicine
Michael S. Louie, Ph.D.
Senior Vice President, Digital Transformation and Chief Information Officer
Almas Qudrat, MSC
Senior Vice President, Quality Operations

Laurent Ducry, Ph.D.
Vice President, Biologics Development and Manufacturing
Bernd Jandeleit, Ph.D.
Vice President, Chemistry
Stephen Raillard, Ph.D.
Vice President, Chemical Development and Manufacturing
Wayne To, M.Phil.
Vice President, Senior Scientific Fellow
Pablo Velazquez-Martin, M.D.
Vice President, Clinical Research and Translational Medicine
Rezi Zawadzki, D.P.H.
Vice President, Biometrics and Clinical Data Science

BOARD OF DIRECTORS

Victor Perlroth, M.D.
Chairman and Chief Executive Officer
Robert A. Profusek, J.D.
Partner and Global Chair M&A, Jones Day
Felix J. Baker, Ph.D.
Managing Director, Baker Brothers Investments
Bassil I. Dahiyat, Ph.D.
President and Chief Executive Officer, Xencor Inc.
Richard S. Levy, M.D.
Formerly Chief Drug Development Officer and Chief Medical Officer, Incyte Corporation
Taiyin Yang, Ph.D.
Formerly Executive Vice President, Pharmaceutical Development & Manufacturing, Gilead Sciences Inc.
Charles Bancroft
Formerly Chief Financial Officer, Bristol Myers Squibb

OUR HISTORY

2009

Jul 2009
Company is founded in Palo Alto, California and focuses on conjugating antibodies and biopolymers to form new medicines

2016

Jan 2016
Company closes first Wall Street institutional financing to fuel retina pipeline

2018

July 2018
Kodiak initiates its first Phase 1a clinical study of KSI-301, an antibody biopolymer conjugate, in patients with diabetic macular edema (DME)
Oct 2018
Kodiak goes public, raising $90 million and is listed on NASDAQ as KOD
Dec 2018
Kodiak presents Phase 1a clinical study data demonstrating safety and durability of response following a single dose of KSI-301 in patients with DME
Dec 2018
Based on promising Phase 1a data in DME, we expand KSI-301 into a Phase 1b study in patients with wet age-related macular degeneration (wAMD), DME and retinal vein occlusion (RVO)
Dec 2018
Kodiak Sciences added to Russell 2000®, 3000® and Microcap® Indexes

2019

Jul 2019
Kodiak presents positive interim data from ongoing Phase 1b clinical study of KSI-301 for the treatment of wet AMD, DME and RVO
Oct 2019
Kodiak treats first patients in DAZZLE, its initial Phase 2b/3 study of KSI-301 in patients with wet AMD
Dec 2019
Kodiak announces sale of future royalties on KSI-301 for $225 million

2020

Oct 2020
Kodiak treats first patients in three Phase 3 pivotal studies of KSI-301—two studies in DME (GLEAM and GLIMMER) and one study in macular edema due to RVO (BEACON)

2021

Feb 2021
Kodiak presents promising 1-year durability, efficacy and safety data from its Phase 1b study of KSI-301 in patients with wet AMD, DME and RVO
June 2021
First patients enrolled in DAYLIGHT pivotal study of KSI-301 in wet AMD
August 2021
First patients enrolled in GLOW study of KSI-301 in patients with non-proliferative Diabetic Retinopathy (DR) without DME

2022

Feb 2022
Kodiak completes enrollment in GLEAM and GLIMMER, its Phase 3 pivotal studies of KSI-301 in patients with DME, with over 900 patients enrolled worldwide
Feb 2022
Top-line results from DAZZLE Phase 2b/3 study in patients with wet AMD announced
May 2022
Learnings from the DAZZLE study informed amendments to GLEAM, GLIMMER and DAYLIGHT
May 2022
Kodiak and Lonza announce grand opening of Kodiak Sciences’ purpose built bioconjugation facility to support potential commercial manufacture of KSI-301
Aug 2022
Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy
Aug 2022
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion